British biopharma company making prescription medicines and vaccines, with a listed India arm in Mumbai and a capability centre in Bengaluru
gsk.comLegal name
GSK plc (formerly GlaxoSmithKline plc)
Founded
27 December 2000
Industry
Pharmaceuticals and biotechnology
Chair
Sir Jonathan Symonds CBE
Employees
About 66,800 worldwide
Revenue (FY2025)
£32.67 billion
Market Cap
£76.09 billion
Listed on
LSE: GSK (FTSE 100). India arm: NSE GLAXO, BSE 500660
GSK plc is a British biopharma company headquartered at 79 New Oxford Street in London. It was formed on 27 December 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, and it trades on the London Stock Exchange under the ticker GSK. The company reported turnover of £32.67 billion in 2025 and employs roughly 66,800 people. Its consumer healthcare business was demerged into Haleon in 2022, so GSK today focuses on prescription medicines and vaccines across specialty medicines, general medicines, HIV, oncology and immunology.
Leadership changed at the top recently. Luke Miels, who joined GSK in 2017 as Chief Commercial Officer, became Chief Executive Officer on 1 January 2026, succeeding Dame Emma Walmsley. Julie Brown has been Chief Financial Officer since May 2023, and Sir Jonathan Symonds CBE chairs the board. In Q1 2026 GSK posted sales of £7.6 billion, up 5% at constant exchange rates, with specialty medicines up 14%, and it reaffirmed full year guidance of 3% to 5% sales growth plus a 2031 outlook of more than £40 billion.
In India, GSK operates through the separately listed GlaxoSmithKline Pharmaceuticals Limited, headquartered at GSK House in Worli, Mumbai. For the year ended 31 March 2026 the India business reported revenue of INR 3,790 crore, up 2%, and profit after tax of INR 1,012 crore, up 10%, with EBITDA margins of 34%. Growth came from brands such as Augmentin, Calpol and T-Bact, the Shingrix vaccine, and oncology products Jemperli and Zejula. GSK also runs a Global Capability Centre in Bengaluru serving global technology, data and medical functions.
Chief Executive Officer, GSK plc
Chief Financial Officer, GSK plc
Managing Director, GSK India
Whole Time Director and Chief Financial Officer, GSK India
Interview experience
8 out of 10, rated favourable
Interview difficulty
Medium, 6 out of 10
Interview process length
About a day or two for most candidates
Practise competency-based questions, get instant feedback, and walk in ready for the STAR format GSK uses.
Q: Define what GSK is?
A: Describe GSK as a British biopharma company that develops prescription medicines and vaccines, formed in 2000 and listed in London and New York. Mention that consumer healthcare left the group as Haleon in 2022, so the focus now is specialty medicines, vaccines, HIV, oncology and immunology.
Q: State your reasons for applying, and why did you select this particular graduate programme?
A: Tie a specific part of the programme to something you've already done, then to where you want to be. Generic praise for the brand won't land; a named rotation, therapy area or capability will.
Q: Give an example of an occasion when you learned an important lesson and how you have applied this to other areas of your life.
A: Use STAR. Set the situation briefly, state what went wrong or what surprised you, name the lesson in one sentence, then give a second, later example where you applied it.
Q: Talk about a subject of interest in the healthcare industry and how it could impact GSK.
A: Pick one topic you can actually discuss, explain the mechanism of impact, then connect it to a part of GSK's business. Depth on one theme beats a list of headlines.
Practise competency-based questions, get instant feedback, and walk in ready for the STAR format GSK uses.
Reported average, all experience levels
₹22,50,000/yr
4 salaries reported Salaries submitted
Reported average, all experience levels
₹18,93,757/yr
8 salaries reported Salaries submitted
Reported average, all experience levels
₹12,34,534/yr
5 salaries reported Salaries submitted
Reported average, entry level
₹11,53,924/yr
3 salaries reported Salaries submitted
Reported average, all experience levels
₹10,45,100/yr
7 salaries reported Salaries submitted
Reported band, average ₹10,26,894
₹1,84,000 to ₹25,00,000/yr
7 salaries reported Salaries submitted
Compare these reported figures against live pharma roles and see where your experience lands.
Worli, Mumbai • Full-time
Mumbai Metropolitan Region • Full-time
Worli, Mumbai • Full-time
Worli, Mumbai • Full-time
Bengaluru, Karnataka • Full-time
Bengaluru, Karnataka • Full-time
Tailor your resume to the exact GSK posting you're applying for, in a couple of minutes.
June 11, 2026
GSK agrees to buy Nuvalent for $10.6 billion
GSK struck a deal for US clinical stage oncology company Nuvalent, one of pharma's biggest oncology acquisitions of 2026, to build out its lung cancer portfolio. CEO Luke Miels called it a multi-product deal for assets with clinically proven targets.
#MergersAndAcquisitions #Oncology #Pharma
View postMay 13, 2026
GSK India reports FY26 revenue of INR 3,790 crore and PAT up 10%
GlaxoSmithKline Pharmaceuticals Limited reported revenue of INR 3,790 crore for the year ended 31 March 2026, with profit after tax of INR 1,012 crore and EBITDA margins of 34%. The board recommended a final dividend of Rs. 57 per share.
#Earnings #IndiaBusiness #Pharma
View postApril 29, 2026
GSK posts Q1 2026 sales of £7.6 billion and reaffirms guidance
GSK reported first quarter turnover of £7.6 billion, up 5% at constant exchange rates, with specialty medicines up 14% and core operating profit up 10%. The company confirmed 2026 guidance of 3% to 5% sales growth and a 2031 outlook above £40 billion.
#Earnings #Biopharma #Guidance
View postJanuary 20, 2026
GSK agrees to acquire RAPT Therapeutics for $2.2 billion
GSK agreed to pay $58.00 per share for RAPT Therapeutics, valuing it at about $2.2 billion, to add ozureprubart, a long acting anti-IgE antibody in phase IIb development for food allergy protection. GSK highlighted the asset's 12-weekly dosing and sustained protection.
#MergersAndAcquisitions #Immunology #Pipeline
View postSeptember 29, 2025
Luke Miels named CEO designate, succeeding Emma Walmsley
GSK announced that Chief Commercial Officer Luke Miels would become Chief Executive Officer from 1 January 2026, taking over from Dame Emma Walmsley. Chair Sir Jonathan Symonds CBE cited Miels' global biopharma development and commercial experience.
#Leadership #CEOTransition #Biopharma
View postGSK is a British biopharma company that develops and sells prescription medicines and vaccines. Its focus areas are specialty medicines, general medicines, vaccines, HIV, oncology and immunology. The consumer healthcare business was demerged as Haleon in 2022.
